Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials

Abstract Purpose We explored the potential overall survival (OS) benefit of bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone (BEACOPP) over doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD) in a pooled analys...

Full description

Bibliographic Details
Main Authors: Marc P. E. André, Patrice Carde, Simonetta Viviani, Monica Bellei, Catherine Fortpied, Martin Hutchings, Alessandro M. Gianni, Pauline Brice, Olivier Casasnovas, Paolo G. Gobbi, Pier Luigi Zinzani, Jehan Dupuis, Emilio Iannitto, Alessandro Rambaldi, Josette Brière, Laurianne Clément‐Filliatre, Marian Heczko, Pinuccia Valagussa, Jonathan Douxfils, Julien Depaus, Massimo Federico, Nicolas Mounier
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Cancer Medicine
Subjects:
ABVD
BEACOPP
Hodgkin lymphoma
overall survival
progression‐free survival
secondary cancers
Online Access:https://doi.org/10.1002/cam4.3298

Internet

https://doi.org/10.1002/cam4.3298

Similar Items